Media & Investors
-
Jun 1, 2020TEGSEDI is first antisense oligonucleotide medicine available to patients in Portugal for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine Regulatory Authority (INFARMED) has granted approval for...
-
May 28, 2020Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy compared to the natural history of the disease
BOSTON and CARLSBAD, Calif., May 28, 2020 - Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
May 18, 2020Michael D. Price brings more than 25 years of experience in the pharmaceutical industry, including in the rare disease sector
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and...
-
May 14, 2020TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the...
-
May 13, 2020
OTTAWA, ON., - May 13, 2020 (CNW) – Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (NASDAQ: AKCA), today announced that it has concluded its negotiation with the...
